Program
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039A
Also written as “MHB039A for Injection” and “MHB039A”.
Its studies are mostly in Breast Neoplasms, led by Minghui Pharmaceutical.
Drug pageAnti-PD-1/Anti-VEGF Bispecific Antibody MHB039A: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 2, since Mar 18, 20243 company-led studies, 3 open or runningNext primary completion: Apr 1, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Minghui Pharmaceutical | 33 open or running | phase 2since Mar 18, 2024 | Mar 18, 2024 | Apr 1, 2028phase 2 · NCT06345482 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 18, 2024First study: phase 2 study in Advanced Solid TumorFirst studyNCT06345482 · 196 enrolled · China
- Aug 11, 20252 phase 2 studiesNCT07126665, NCT07130383
Ahead
- Apr 1, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT06345482
- Aug 2029Primary completion: phase 2 study in Advanced Breast CancerNCT07130383
- Aug 2029Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07126665
TargetBeta
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| tivunatamig | Pfizer | phase 3 | 15 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 | Merck | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rule | wigen-biomedicine-technology-shanghai-co-ltd | phase 2 | 2 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rule | compass-therapeutics | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07130383Advanced Breast Cancer · China | 2 | Recruiting | Aug 2029 | 210 |
| NCT07126665Advanced Malignant Solid Tumor · China | 2 | Recruiting | Aug 2029 | 116 |
| NCT06345482Advanced Solid Tumor · China | 2 | Active, not recruiting | Apr 1, 2028 | 196 |
How it is read
Names in the registry
- “MHB039A for Injection”, 2 entries
- “MHB039A”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.